D.A. Davidson & CO. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 538,338 shares of the company’s stock after purchasing an additional 2,937 shares during the period. Johnson & Johnson accounts for 1.4% of D.A. Davidson & CO.’s investment portfolio, making the stock its 6th biggest holding. D.A. Davidson & CO.’s holdings in Johnson & Johnson were worth $69,989,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Eagle Ridge Investment Management grew its stake in Johnson & Johnson by 3.5% in the 3rd quarter. Eagle Ridge Investment Management now owns 27,522 shares of the company’s stock valued at $3,578,000 after buying an additional 928 shares in the last quarter. Welch & Forbes LLC grew its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after buying an additional 6,730 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Johnson & Johnson by 0.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after buying an additional 3,533 shares in the last quarter. Oliver Luxxe Assets LLC grew its stake in Johnson & Johnson by 12.7% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock valued at $2,320,000 after buying an additional 1,972 shares in the last quarter. Finally, Progressive Investment Management Corp grew its stake in Johnson & Johnson by 6.8% in the 3rd quarter. Progressive Investment Management Corp now owns 40,317 shares of the company’s stock valued at $5,242,000 after buying an additional 2,584 shares in the last quarter. Institutional investors own 65.58% of the company’s stock.
In other news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE JNJ) opened at $132.02 on Friday. The company has a market cap of $354,670.00, a price-to-earnings ratio of 24.31, a PEG ratio of 2.18 and a beta of 0.74. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $120.90 and a 1 year high of $148.32.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The company had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the previous year, the firm posted $1.58 EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. sell-side analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 61.88%.
JNJ has been the subject of a number of recent research reports. BTIG Research reiterated a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective for the company. in a research note on Monday, January 8th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets lifted their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $146.16.
TRADEMARK VIOLATION NOTICE: “D.A. Davidson & CO. Raises Stake in Johnson & Johnson (JNJ)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/24/d-a-davidson-co-raises-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.